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Papillary thyroid cancer (PTC) is the most common thyroid malignancy. Genetic and epigenetic alterations play a decisive role in
the onset of several human neoplasms. Mutations and polymorphisms are two frequent genetic alterations. Located on
chromosome 19 (19p13.11), the NIS SLC5A5 (solute carrier family 5 member 5) gene encodes a highly specialized and eﬃcient
80–90 kDa transmembrane glycoprotein that mediates active transport of iodide from the bloodstream into the follicular cells.
Given the highly signiﬁcant role of NIS in the physiology and the cancer pathogenesis process, this paper’s objective is to
provide a comprehensive assessment of the associations between NIS gene and protein with papillary thyroid cancer.
1. Introduction
The thyroid gland is one of the largest glands in the human
body. Located anterolaterally to the trachea and larynx, it
consists of two lobes connected by an isthmus. It is composed
histologically of two main types of parenchymal cells: the fol-
licular ones, where there is a higher concentration of iodine
and the production of thyroid hormones (HT) T3 and T4,
and the parafollicular cells, in which the hormone calcitonin
is produced. There are reports that from the follicular cells
emerge the well-diﬀerentiated cancers (papillary and follicu-
lar), whereas in the parafollicular region originate medullary
carcinoma [1].
The incidence of thyroid cancer is increasing among men
and women, driven by the papillary subtype, representing
approximately 90% of cases. When comparing the incidence
by gender, the rates are higher in women than in men, of
which the greater representativeness is in whites, besides
increasing with age [2].
Mortality rates are highest in the Melanesian region, in
some regions of Africa, as well as in countries with lower
levels of human development, although the highest rates of
incidence are reported in some European countries and
North America. Nevertheless, the highest overall incidence
is in the Republic of Korea, where thyroid cancer is the most
common cancer among women [3].
In Brazil, for the years 2016 and 2017, 1090 new cases
were expected for males and 5870 for females, with an esti-
mated risk of 0.97 cases per 100,000 males and 5.62 cases
per 100,000 females [4]. In the United States, the results
showed that from 1975 to 2014, the incidence almost tripled,
from 4.9 to 14.3 per 100,000 individuals. Substantially all of
the increase was attributed to papillary thyroid cancer
(PTC) (from 3.4 to 12.5 per 100,000). However, it was con-
cluded that there is no epidemic of the disease in the United
States but rather a diagnostic epidemic [5].
PTC is the most common endocrine malignancy
accounting for approximately 80–85% of cases [1]. Radiation
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exposure, age, female gender, and family history are some
risk factors that increase the incidence of well-diﬀerentiated
thyroid cancer. Epidemiological studies have demonstrated
an increased risk of four to ten times greater in individuals
with ﬁrst-degree relatives with this neoplasm [6].
A retrospective case-control study with 255 patients
evaluated possible associations between single nucleotide
polymorphisms (SNPs) in the ATM, XRCC1, TP53, XRCC3,
and MTF1 genes with associated PTC risk. The results
showed that SNPs in exon 39 of the ATM gene and the
exon 10 of the XRCC1 gene may be the markers of pro-
tection in adults’ PTC, whereas, in the SNPs of ATM,
IVS22-77 and TP53 genes at codon 72 may be associated
with the risk of PTC development in nonirradiated and
irradiated subjects [7].
Activation of the MAPK and PI3K/AKT signaling
pathways appears to be crucial for the initiation and pro-
gression of thyroid cancer [8]. The BRAF and RAS genes
are also commonly found in TCs, as well as the changes
involving RET/PTC and PAX8/PPAR-γ chromosomal rear-
rangements [9, 10].
A genomic association study of nonmedullary thyroid
cancer included 3.001 patients and 287.550 controls from
ﬁve study groups of European descent. The results showed
ﬁve new loci (all with combined P < 3 × 10−8): 1q42.2
(rs12129938 in PCNXL2), 3q26.2 (rs6793295 a missense
mutation in LRCC34 next to TERC), 5q22.1 (rs73227498
between NREP and EPB41L4A), 10q24.33 (rs7902587
close to OBFC1), and two variants independently associ-
ated with 15q22.33 (rs2289261 and rs56062135, both in
SMAD3) [11].
Another paper describes the genomic situation of 496
PTCS: a low frequency of somatic alterations (relative to
other carcinomas) and an extension of the set of known
PTC driver alterations to include EIF1AX, PPM1D, and
CHEK2 and diverse gene fusions. These grouped analyses
of gene expression, genomic variants, and methylations have
demonstrated that diﬀerent groups lead to diﬀerent patholo-
gies with distinct characteristics of signaling and diﬀerentia-
tion [12].
Located on chromosome 19 (19p13.11), the NIS SLC5A5
(solute carrier family 5 member 5) gene encodes a highly spe-
cialized and eﬃcient 80–90 kDa transmembrane glycopro-
tein that mediates active transport of iodide from the
bloodstream into the follicular cells. This transport occurs
via the sodium gradient generated by the Na+/K+-ATPase
pump, transporting two sodium cations to an iodide anion
as the crucial ﬁrst step in the biosynthesis of thyroid hor-
mones [13, 14]. NIS (SLC5A5) is also present in other tissues,
such as gastric mucosa, choroid plexus, ciliary body of the eye,
salivary and lacrimal glands, pulmonary airway, placenta, and
mammary glands in the lactation period [15, 16]. The activity
of NIS (SLC5A5) is mainly regulated by the thyroid-
stimulating hormone (TSH), which consequently participates
in the regulation of iodine uptake by follicular cells mediated
by cAMP [15].
Given the highly signiﬁcant role of NIS (SLC5A5) in the
physiology and the cancer pathogenesis process, this paper’s
objective is to provide a comprehensive assessment of the
associations between the NIS (SLC5A5) gene and protein
with papillary thyroid cancer.
2. Materials and Methods
2.1. Search Strategy. The literature search was carried out
through the PubMed portal, on December 27, 2017, for all
types of studies which may indicate the relationship between
the NIS (SLC5A5) gene and susceptibility to papillary thy-
roid cancer. The following search terms were used: “NIS,”
“thyroid,” “cancer,” and “papillary thyroid carcinoma.” The
retrieved articles were selected by reviewers to identify
search-related studies, as viewed in (Figure 1).
2.2. Filters and Inclusion and Exclusion Criteria. There were
no restrictions regarding language, year, species, and types
of studies in the bibliographic research. The inclusion criteria
were as follows: (1) the study should relate the NIS gene to
papillary thyroid cancer, even if associated with other
comorbidities and with other genes; (2) the study should
provide data for analysis. The studies were excluded if (1)
they were clinical case studies, (2) they were studies with
insuﬃcient available data, and (3) they presented data from
other types of thyroid cancer or did not specify what type
the patients presented.
2.3. Data Extraction. The data from the eligible studies were
independently extracted according to the inclusion and
exclusion criteria. For each study, the following characteris-
tics were collected: authors, study title, objective, year of
publication, the country in which it was published, sample
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3. Results and Discussion
The systematic search found thirty-eight publications, between
1996 and 2017, of which nineteen met the inclusion criteria
and are represented chronologically in Table 1.
Of the articles selected, ﬁve were published in China, four
in the Republic of Korea, three in Italy, two in the United
States, and two in Brazil, followed by Spain, Turkey, and
Poland with one each (Figure 2).
3.1. Expression, Localization, and Regulation of NIS
(SLC5A5). For years, lack of information on NIS (SLC5A5)
built a signiﬁcant gap in the understanding of thyroid patho-
physiology. No molecular information of this gene was avail-
able until the year 1996 when Smanik et al. [35] reported the
sequence of 1929 nucleotides that encode the NIS (SLC5A5)
protein with 643 amino acids, thus proposing possible lines
of investigations about its regulatory mechanisms and factors
related to thyroid diseases [13, 35]. Since then, several studies
have demonstrated the importance of the gene in the
hormonal synthesis, iodine therapy, and physiology of the
thyroid gland.
The NIS (SLC5A5) gene has also been reported in other
tissues, such as in human testes, an important factor in pre-
dicting the accumulation of radioiodine in the gonads of
men with thyroid cancer exposed to treatment, although
the concentration represents levels 10 times lower than in
thyroid tissues [36].
For the iodine transport which occurs from the blood-
stream to the intracellular medium, the location of the NIS
protein should be basolateral to the thyroid cell [37]. Wei
et al. [26] demonstrated changes in protein expression of
NIS in PTC, mainly located in the cytoplasm and rarely in
the basolateral membrane when compared with healthy indi-
viduals; nonetheless, these data were not statistically signiﬁ-
cant (P = 0 675). Conversely, in tumors considered small
(<1 cm), it presented a statistically signiﬁcant diﬀerence
(P = 0 037). Other locations have also been described, in
another Chinese work, such as in the nucleus, in conven-
tional PTC (P < 0 001) [26].
Another study demonstrated that NIS staining was local-
ized almost exclusively to the plasma membrane in normal
thyroid tissues but less intensely in tumor tissues [31].
Additionally, the positivity and the intensity of NIS expres-
sion were statistically higher between healthy and cancerous
cells in a Korean study (P < 0 001) [18].
Anarticle published in Italy in2015 found thatNIS expres-
sion levels in tumor tissue were lower than those in a healthy
correspondent (P < 0 001). Furthermore, the expression of
thyroid hormone receptor Beta (THRβ) when compared to
the NIS (SLC5A5) gene mRNA levels presented a statistically
signiﬁcant positive correlation (r=0.3771, P = 0 0098) [30].
Another study demonstrated that NIS staining was local-
ized almost exclusively on the plasma membrane in normal
thyroid tissues but less intense in tumor tissues [31]. Other
genes have also been identiﬁed as related to NIS (SLC5A5).
The BRAFV600E alteration is the most common in PTC,
with a worldwide prevalence of 29 to 83% [38]. Riesco-
Eizaguirre et al. [17] sought to investigate the role of
BRAFV600E and MEK-ERK (protein chain that communi-
cates a signal from the receptor on the surface of the cell to
DNA) in thyroid dediﬀerentiation. After immunohistochem-
ical analysis, the NIS staining was negative or weakly positive
and not localized to the membrane in most BRAFV600E ver-
sus BRAFwt samples (P = 0 005), and there is a limited role
of the MEK-ERK pathway in this impairment. Likewise, in
the Korean article, in the standard cell thyroid, the NIS stain-
ing was predominantly observed in the plasma membrane.
However, the NIS presence was also located in the cytoplasm
of cancer cells [18].
The functional expression of NIS, which allows the
interiorization of iodine, was higher in patients with the
BRAFV600E mutation (78.1%) than in those with the
ancestral genotype (57.1%) (P = 0 047), while the nonfunc-
tional NIS expression was lower in the BRAFV600E-
positive mutation group (21.3%) than in the negative
mutation group (42.9%) (P = 0 047) [33]. Therefore, it sim-
ilar to those analyzed by Kleiman et al. [24], where the
expression of NIS in the group of patients with TC (of
which 86.5% were with PTC) with the BRAFV600E mutation
was lower (0.27± 0.03) compared to BRAFwt (0.78± 0.09)
(P < 0 01).
Given the regulation between BRAFwt gene expres-
sion and inhibition of NIS expression, the mutation in
BRAFV600E did not inhibit NIS expression (P = 0 085) in
PTC. However, in concomitance with Hashimoto’s thyroid-
itis, there was less NIS expression after the adjustment for
confounding factors (P = 0 046) [32]. However, for the ﬁrst
time, it was described in one paper, through an important
epigenetic mechanism by histone deacetylation in the
BRAFV600E gene, through the mechanism of chromatin
compaction and the blocking of the promoters of the binding
gene with transcription factors, resulting in the silencing of
the NIS (SLC5A5) gene [39].
NIS expression was downregulated in BRAFV600E when
expressed in normal primary thyrocytes isolated from tissues
via lentiviral transduction (P < 0 01). By induction of meth-
ylation on the CpG island of the promoter region,
BRAFV600E reduced NIS expression (29% in healthy cells
versus 58% in PTC). Furthermore, real-time PCR showed
that DNMT1 and NIS expression were inversely correlated
with BRAFV600E (P < 0 01) [28].
China
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Figure 2: Quantities and rates of publications by country of selected
publications using the inclusion criteria.
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The FoxP3 transcription factor is an intracellular mole-
cule that suppresses antitumor responses that maintain the
immune balance in host tissues. The high presence of FoxP3
in tissues is usually associated with an unfavorable outcome,
so they are used to deﬁne prognosis and even new therapeutic
targets [40]. Ma et al. [31] analyzed the NIS staining in the
FoxP3-positive and FoxP3-negative groups. The positive
group had a lower NIS staining rate (31.8%) than the negative
one (66.7%) (P < 0 01). Furthermore, NIS transcript levels
were signiﬁcantly reduced in the tumor sample relative
to normal tissue and in FoxP3-positive samples against
FoxP3-negative samples (P < 0 001). The transforming
growth factor-β1 (TGF-β1) was also explored. PTC cell sam-
ples were pretreated with TGF-β1 for 24h. After analysis,
NIS protein and transcript levels were found to decrease,
reaching the minimum concentration of 10 ng/mL TGF-β1
when compared to the control (P < 0 01).
Smith et al. [19] sought to determine the methylation
status of NIS (SLC5A5) promoter regions and to associate
them with patients with papillary thyroid carcinoma. The
results showed a higher methylation frequency in the
malignant tissue when compared to the controls (P < 0 05
), and in all controls, the promoter regions for NIS were
not methylated. There was no statistical diﬀerence in the
proportion of nodular metastasis between the methylated
and unmethylated NIS samples (P = 0 17). The majority
(57%) of the methylated NIS specimens presented nodular
metastasis against 24% of the nonmethylated ones. More-
over, when tumor cells with adjacent healthy tissue were
compared, methylation was only present in the pathologi-
cal tissue.
NIS expression was also lower in BRAFV600E compared
to the BRAFwt group in classic PTC (P < 0 0001) and PTC
follicular variant (P = 0 0325) [20]. In a Brazilian study with
148 patients with diﬀerentiated thyroid cancer (DTC), of the
thirteen that died, all tested negative for NIS in immunohis-
tochemistry, in addition to weakly expressing mRNA of the
gene [21]. In the same study, it was possible to observe that
NIS expression was lower in PTC BRAFV600E (P = 0 0388
), although it was not possible to identify individuals with
worse prognosis after mRNA (P = 0 4037) and immunohis-
tochemical analyses.
In order to analyze whether NIS expression was associ-
ated with the expression of BRAFV600E, Choi et al. [28]
found that 65% of healthy thyroid follicle samples showed
standard staining in the plasma membrane region. However,
the membrane staining was reduced in PTC with a positive
BRAFV600E. Moreover, 37% of PTC tissues exhibited diﬀuse
cytoplasmic staining.
Unlike the natural physiology of the thyroid, NIS
expression in the analyzed studies is impaired, corroborat-
ing the idea that alterations in the NIS SLC5A5 gene can
lead to worse prognosis, due to the ineﬀectiveness of the
radioiodine, though, in some studies, it is not possible to
identify this through immunohistochemical analyzes
(P = 0 4037) [21]. Patients with metastases in the region of
the neck without uptake of 131I revealed a slight reduction
in NIS transcripts when compared to primary patients
(P = 0 05) [41]. NIS expression was higher in patients with
TC well diﬀerentiated (0.67± 0.20) when compared to the
less diﬀerentiated (0.36± 0.05) (P = 0 0001). Furthermore,
there appears to be a competition of NIS SLC5A5 and
GLUT-1 gene expression (r = −0 60, P < 0 01), positive cor-
relation of NIS and TG (r = 0 52, P < 0 05), and NIS and
pendrin (r = 0 77, P < 0 05) [27].
In most thyroid carcinomas, NIS mRNA levels are
reduced when compared to adenomas and normal adjacent
thyroid tissue [42]. In the study by Qin et al. [22], the posi-
tive expression of the NIS gene (70.3%) was statistically sig-
niﬁcant in patients with DTC (including PTC and FTC)
when compared to follicular adenoma (P = 0 013). NIS gene
expression was lower in PTC than in healthy tissue [41].
Normal thyroid cells express phosphodiesterase subtypes
PDE4, PDE5, PDE7, and PDE8 [43]. Analyzing the PDE5
expression in surgical specimens of human papillary thyroid
tumor tissues related to the gene BRAFV600E and NIS
SLC5A5, Sponziello et al. concluded that all analyzed samples
had higher levels of PDE5A expression compared to control
samples. However, expression levels of NIS mRNA were
decreased in PTC (P < 0 0001) [29].
3.2. The Role of NIS in Thyrocytes. The decay of 131I occurs by
β-emission (606 keV) with 89% abundance of high energy γ-
emission (364 keV). After its oral administration, it is rapidly
absorbed in the gastrointestinal tract and then distributed to
the thyroid and other organs. In the thyroid gland, the iodide
is then internalized by the epithelial cells by active transport
through the NIS protein. In addition to 131I, other radionu-
clides are also absorbed by thyroid cells and tissues, such as
123I, 124I, 99mTc, 111In, 18F, 11C, and 68Ga [44].
The thyroid internalizes iodine through a series of meta-
bolic steps which include some proteins such as pendrin
(PD), thyroid peroxidase (TPO), and thyroglobulin (Tg), in
addition to NIS [27].
The comparison of the uptake of FDG-F18 with the
expression of GLUT1 and NIS in tumors of PTC patients
undergoing thyroidectomy concluded that the maximum
uptake pattern (SUV) in NIS-negative lesions was signiﬁ-
cantly higher than that in positive lesions (P = 0 006) [23].
Choi et al. found that there is no eﬃcient iodide absorp-
tion when BRAFV600E is expressed in thyrocytes, resulting
in inhibition of NIS expression in both PTC and isolated pri-
mary thyrocytes (P < 0 01) [28].
Positive regulationofNISprotein expressionwasobserved
in a Polish study in the K1 cell groups receiving lower (5Gy)
and higher (20Gy) doses after 24 h with 131I (P < 0 05). How-
ever, after 72 h of culture without iodine, there was a reversal
in regulation. Furthermore, changes in the 8-oxo-dG level
were observed in cells treated with the lowest dose (5Gy)
when compared to the control group. The concentration
increased only at the 96h time point, indicating prolonged
accumulation of DNA damage even after the completion of
irradiation with 131I (P < 0 01) [34].
Several ﬁndings on the expression of genes in thyroid
disease have shown that levels of mRNA-encoding NIS,
thyrotropin receptor (TSH-R), thyroid peroxidase, and
thyroglobulin (Tg), among other factors, are decreased in
malignant tumors of the thyroid compared to controls [45].
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4. Conclusion
The studies of genetic factors are of paramount importance
for diagnosis, treatment, eﬃcacy, and better prognosis in
patients with papillary thyroid cancer. Although changes of
these factors are not yet fully implemented and understood,
identifying the presence of these alterations may allow early
intervention of researchers and health professionals. The
eﬀectiveness of radioactive iodine (radioiodine) therapy
depends not only on the role of the NIS SLC5A5 gene but
also, conceivably, on the reduction of other molecules that
regulate its intracellular metabolism.
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